



## VÉTOQUINOL MARKETS CEFTIOCYL® AND KEFLORIL® TWO NEW INJECTABLE ANTIBIOTICS FOR LIVESTOCK

Lure, December 15, 2010 – In line with recent announcements, Vétoquinol is launching Ceftiocyl® and Kefloril®, two new injectable antibiotics for livestock. The products are being brought to market by the Group and its subsidiaries in both domestic and export markets.

In a key strategic area for the Group, Vétoquinol is reinforcing its range of anti-infection products with the launch of Ceftiocyl® and Kefloril®, now registered in the majority of European national markets.



- Ceftiocyl® is an antibiotic in the cephalosporin family, indicated for cows suffering uterine infections after calving, and for cattle suffering localized hoof or lower leg infection. Ceftiocyl® is also indicated for the treatment of respiratory infections in pigs.
- Kefloril® is an antibiotic in the fenicolate family indicated for the treatment of respiratory infections in cattle and pigs.

By launching these two new products, Vétoquinol is extending its range of targeted medication and reinforcing its stance as a specialist developer of antibiotics, thereby increasing market share in medicines for livestock welfare.

Vétoquinol CEO Matthieu Frechin declared his satisfaction at the launch of these new products and declared: "Our range of injectable antibiotics has expanded to five outstanding products (*Marbocyl 10%*, *Marbocyl 2%*, *Marbocyl S*, *Ceftiocyl* and *Kefloril*) which are targeted to our customer needs. We now cover most of the infectious pathologies encountered by veterinarians in their daily practice. Vétoquinol is pursuing its responsible approach to the use of antibiotics while marketing a range of differentiated drugs targeting specific pathologies."

**About Vétoquinol**

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the 10<sup>th</sup> largest animal healthcare laboratory in the world. More than 80% of its revenues are generated outside France.

Vétoquinol's business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology.

The Group currently distributes its products in more than one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 23 countries and a network of 140 distribution partners. The company has more than 1,600 employees worldwide.

For more information: [www.vetoquinol.com](http://www.vetoquinol.com).

**OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.**

For more information, contact:

**VETOQUINOL**

Finance department

Marie-Josée AUBRY-ROTA

Tel.: 03 84 62 59 88

[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

**KEIMA COMMUNICATION**

Investor relations

Emmanuel DOVERGNE

Tel.: 01 56 43 44 63

[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)

Media relations

Sibylle DESCAMPS

Tel.: 01 56 43 44 72

[sibylle.descamps@keima.fr](mailto:sibylle.descamps@keima.fr)